ICYMI: Biosimilar BI 695501 Has Similar Safety and Efficacy to Adalimumab for the Treatment of Crohn’s Disease: VOLTAIRE-CD Study
Evidence-Based GI: An ACG Publication and Podcast - Un pódcast de American College of Gastroenterology - Miercoles
Philip Schoenfeld, MD, MSEd, MSc (Epi) and Rahul Dalal, MD, MPH discuss “Safety and efficacy of BI 695501 versus adalimumab reference product in patients with advanced Crohn's disease (VOLTAIRE-CD): a multicentre, randomised, double-blind, phase 3 trial,” by Hanauer S, Liedert B, Balser S, et al. Lancet Gastroenterol Hepatol. 2021 Oct;6(10):816-825. Epub 2021 Aug 11.
